Private Equity
Andrea Alms Video: Money In Motion 108 - Cancer Immunotherapy - CAR T-cell Therapy Market
June 2024 - Private Equity
TRANSCRIPT Hello, my name is Andrea Alms. I am a technology investor and financial manager and this is your money in motion. As you may recall from a previous episode, we reviewed the market sizes of the various cancer treatment options. The most lucrative market was a category called immunotherapy as a review. Immunotherapy is a cancer treatment that boosts the body's immune system. To fight cancer, your body's immune system detects something harmful.
Your body starts to produce antibodies and proteins that fight infection, as opposed to traditional cancer therapies that kill both healthy and cancer cells. As review averaging the averages, the global immunotherapy market size is 131.8 billion at a 12.1% compound average growth rate. Triple digit market size growing at double digit growth. Just to be clear, immunotherapy is a general name for this category of cancer treatment.
There are specific drug and therapies such as car T cell therapy. As you can see from the diagram Car-T cell therapy, the patient's blood is collected, the patient's T cells are reprogramed and infused back into the patient. According to marketing U.S., the global Car-T cell therapy market is 2.8 billion U.S. dollars in 2023, expected to be 10 billion by 2033 at a compound average growth rate of 13.8% at Zions Market Research in 2022, the market size was 378.49 million.
It is forecast to be 2.4 billion by 2030, at a growth rate of 26.2%. A Vision Research reports. In 2023, the market size was 3.71 billion. It is expected to grow to 30.25 billion by 2033, with a compound average growth rate of 23.4%, averaging the averages. The market size is 2.3 billion added 21.1% growth rate. Thank you. This is your money, your money, in motion.